Rhinophototherapy in persistent allergic rhinitis

Zsolt Bella, Ágnes Kiricsi, Éva Dósa Rácz Viharosné, Attila Dallos, Ádám Perényi, M. Kiss, Andrea Koreck, L. Kemény, József Jóri, László Rovó, Edit Kadocsa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Previous published results have revealed that Rhinolight® intranasal phototherapy is safe and effective in intermittent allergic rhinitis. The present objective was to assess whether phototherapy is also safe and effective in persistent allergic rhinitis. Thirty-four patients with persistent allergic rhinitis were randomized into two groups; twenty-five subjects completed the study. The Rhinolight® group was treated with a combination of UV-B, UV-A, and high-intensity visible light, while the placebo group received low-intensity visible white light intranasal phototherapy on a total of 13 occasions in 6 weeks. The assessment was based on the diary of symptoms, nasal inspiratory peak flow, quantitative smell threshold, mucociliary transport function, and ICAM-1 expression of the epithelial cells. All nasal symptom scores and nasal inspiratory peak flow measurements improved significantly in the Rhinolight® group relative to the placebo group and this finding persisted after 4 weeks of follow-up. The smell and mucociliary functions did not change significantly in either group. The number of ICAM-1 positive cells decreased non-significantly in the Rhinolight® group. No severe side-effects were reported during the treatment period. These results suggest that Rhinolight® treatment is safe and effective in persistent allergic rhinitis.

Original languageEnglish
Pages (from-to)1543-1550
Number of pages8
JournalEuropean Archives of Oto-Rhino-Laryngology
Volume274
Issue number3
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Phototherapy
Nose
Smell
Intercellular Adhesion Molecule-1
Placebos
Mucociliary Clearance
Light
Epithelial Cells
Allergic Rhinitis
Therapeutics

Keywords

  • Intercellular adhesion molecule-1 expression
  • Intranasal phototherapy
  • Mucociliary clearance
  • Nasal inspiratory peak flow
  • Persistent allergic rhinitis
  • Rhinolight

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Bella, Z., Kiricsi, Á., Viharosné, É. D. R., Dallos, A., Perényi, Á., Kiss, M., ... Kadocsa, E. (2017). Rhinophototherapy in persistent allergic rhinitis. European Archives of Oto-Rhino-Laryngology, 274(3), 1543-1550. https://doi.org/10.1007/s00405-016-4358-x

Rhinophototherapy in persistent allergic rhinitis. / Bella, Zsolt; Kiricsi, Ágnes; Viharosné, Éva Dósa Rácz; Dallos, Attila; Perényi, Ádám; Kiss, M.; Koreck, Andrea; Kemény, L.; Jóri, József; Rovó, László; Kadocsa, Edit.

In: European Archives of Oto-Rhino-Laryngology, Vol. 274, No. 3, 01.03.2017, p. 1543-1550.

Research output: Contribution to journalArticle

Bella, Z, Kiricsi, Á, Viharosné, ÉDR, Dallos, A, Perényi, Á, Kiss, M, Koreck, A, Kemény, L, Jóri, J, Rovó, L & Kadocsa, E 2017, 'Rhinophototherapy in persistent allergic rhinitis', European Archives of Oto-Rhino-Laryngology, vol. 274, no. 3, pp. 1543-1550. https://doi.org/10.1007/s00405-016-4358-x
Bella Z, Kiricsi Á, Viharosné ÉDR, Dallos A, Perényi Á, Kiss M et al. Rhinophototherapy in persistent allergic rhinitis. European Archives of Oto-Rhino-Laryngology. 2017 Mar 1;274(3):1543-1550. https://doi.org/10.1007/s00405-016-4358-x
Bella, Zsolt ; Kiricsi, Ágnes ; Viharosné, Éva Dósa Rácz ; Dallos, Attila ; Perényi, Ádám ; Kiss, M. ; Koreck, Andrea ; Kemény, L. ; Jóri, József ; Rovó, László ; Kadocsa, Edit. / Rhinophototherapy in persistent allergic rhinitis. In: European Archives of Oto-Rhino-Laryngology. 2017 ; Vol. 274, No. 3. pp. 1543-1550.
@article{eb434955930d4ffbb5d50c1a1faea7f1,
title = "Rhinophototherapy in persistent allergic rhinitis",
abstract = "Previous published results have revealed that Rhinolight{\circledR} intranasal phototherapy is safe and effective in intermittent allergic rhinitis. The present objective was to assess whether phototherapy is also safe and effective in persistent allergic rhinitis. Thirty-four patients with persistent allergic rhinitis were randomized into two groups; twenty-five subjects completed the study. The Rhinolight{\circledR} group was treated with a combination of UV-B, UV-A, and high-intensity visible light, while the placebo group received low-intensity visible white light intranasal phototherapy on a total of 13 occasions in 6 weeks. The assessment was based on the diary of symptoms, nasal inspiratory peak flow, quantitative smell threshold, mucociliary transport function, and ICAM-1 expression of the epithelial cells. All nasal symptom scores and nasal inspiratory peak flow measurements improved significantly in the Rhinolight{\circledR} group relative to the placebo group and this finding persisted after 4 weeks of follow-up. The smell and mucociliary functions did not change significantly in either group. The number of ICAM-1 positive cells decreased non-significantly in the Rhinolight{\circledR} group. No severe side-effects were reported during the treatment period. These results suggest that Rhinolight{\circledR} treatment is safe and effective in persistent allergic rhinitis.",
keywords = "Intercellular adhesion molecule-1 expression, Intranasal phototherapy, Mucociliary clearance, Nasal inspiratory peak flow, Persistent allergic rhinitis, Rhinolight",
author = "Zsolt Bella and {\'A}gnes Kiricsi and Viharosn{\'e}, {{\'E}va D{\'o}sa R{\'a}cz} and Attila Dallos and {\'A}d{\'a}m Per{\'e}nyi and M. Kiss and Andrea Koreck and L. Kem{\'e}ny and J{\'o}zsef J{\'o}ri and L{\'a}szl{\'o} Rov{\'o} and Edit Kadocsa",
year = "2017",
month = "3",
day = "1",
doi = "10.1007/s00405-016-4358-x",
language = "English",
volume = "274",
pages = "1543--1550",
journal = "Archiv fur klinische und experimentelle Ohren- Nasen- und Kehlkopfheilkunde",
issn = "0003-9195",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Rhinophototherapy in persistent allergic rhinitis

AU - Bella, Zsolt

AU - Kiricsi, Ágnes

AU - Viharosné, Éva Dósa Rácz

AU - Dallos, Attila

AU - Perényi, Ádám

AU - Kiss, M.

AU - Koreck, Andrea

AU - Kemény, L.

AU - Jóri, József

AU - Rovó, László

AU - Kadocsa, Edit

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Previous published results have revealed that Rhinolight® intranasal phototherapy is safe and effective in intermittent allergic rhinitis. The present objective was to assess whether phototherapy is also safe and effective in persistent allergic rhinitis. Thirty-four patients with persistent allergic rhinitis were randomized into two groups; twenty-five subjects completed the study. The Rhinolight® group was treated with a combination of UV-B, UV-A, and high-intensity visible light, while the placebo group received low-intensity visible white light intranasal phototherapy on a total of 13 occasions in 6 weeks. The assessment was based on the diary of symptoms, nasal inspiratory peak flow, quantitative smell threshold, mucociliary transport function, and ICAM-1 expression of the epithelial cells. All nasal symptom scores and nasal inspiratory peak flow measurements improved significantly in the Rhinolight® group relative to the placebo group and this finding persisted after 4 weeks of follow-up. The smell and mucociliary functions did not change significantly in either group. The number of ICAM-1 positive cells decreased non-significantly in the Rhinolight® group. No severe side-effects were reported during the treatment period. These results suggest that Rhinolight® treatment is safe and effective in persistent allergic rhinitis.

AB - Previous published results have revealed that Rhinolight® intranasal phototherapy is safe and effective in intermittent allergic rhinitis. The present objective was to assess whether phototherapy is also safe and effective in persistent allergic rhinitis. Thirty-four patients with persistent allergic rhinitis were randomized into two groups; twenty-five subjects completed the study. The Rhinolight® group was treated with a combination of UV-B, UV-A, and high-intensity visible light, while the placebo group received low-intensity visible white light intranasal phototherapy on a total of 13 occasions in 6 weeks. The assessment was based on the diary of symptoms, nasal inspiratory peak flow, quantitative smell threshold, mucociliary transport function, and ICAM-1 expression of the epithelial cells. All nasal symptom scores and nasal inspiratory peak flow measurements improved significantly in the Rhinolight® group relative to the placebo group and this finding persisted after 4 weeks of follow-up. The smell and mucociliary functions did not change significantly in either group. The number of ICAM-1 positive cells decreased non-significantly in the Rhinolight® group. No severe side-effects were reported during the treatment period. These results suggest that Rhinolight® treatment is safe and effective in persistent allergic rhinitis.

KW - Intercellular adhesion molecule-1 expression

KW - Intranasal phototherapy

KW - Mucociliary clearance

KW - Nasal inspiratory peak flow

KW - Persistent allergic rhinitis

KW - Rhinolight

UR - http://www.scopus.com/inward/record.url?scp=84995755286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995755286&partnerID=8YFLogxK

U2 - 10.1007/s00405-016-4358-x

DO - 10.1007/s00405-016-4358-x

M3 - Article

VL - 274

SP - 1543

EP - 1550

JO - Archiv fur klinische und experimentelle Ohren- Nasen- und Kehlkopfheilkunde

JF - Archiv fur klinische und experimentelle Ohren- Nasen- und Kehlkopfheilkunde

SN - 0003-9195

IS - 3

ER -